A Looming Threat for Arena and VIVUS
In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article A Looming Threat for Arena and VIVUS originally appeared on Fool.com.David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.